MCE Molecular Imaging for Myocarditis
Key facts
- Where
- Charlottesville, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- University of VirginiaCharlottesville, United StatesContact: Jonathan Lindner, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Virginia
- Trial code
- NCT07538544
- Record updated
- 20 August 2026
- Original description
Inflammation of the heart (myocarditis) is a serious condition that can cause heart failure, abnormal heart rhythms, cardiac arrest, and death. Rapid diagnosis of this condition is key to reversing it. The purpose of this study is to determine whether myocarditis such as that which occurs with viral illness, autoimmune conditions, or certain therapies (i.e. immune checkpoint inhibitors) can be diagnosed using a new form of ultrasound imaging of the heart (echocardiography) that uses a contrast agent that is targeted to inflammation (Sonazoid).Read full original descriptionShow less
MCE Molecular Imaging in Myocarditis
Inflammation of the heart (myocarditis) is a serious condition that can cause heart failure, abnormal heart rhythms, cardiac arrest, and death. Rapid diagnosis of this condition is key to reversing it. The purpose of this study is to determine whether myocarditis such as that which occurs with viral illness, autoimmune conditions, or certain therapies (i.e. immune checkpoint inhibitors) can be diagnosed using a new form of ultrasound imaging of the heart (echocardiography) that uses a contrast agent that is targeted to inflammation (Sonazoid).
Inclusion: Age ≥18 years of age; At least two of the following manifestations of myocarditis:; new or suspected new high-sensitivity troponin >3 times upper limit of normal; new or suspected new LV dysfunction with LVEF <50% or any segmental wall motion abnormality in the absence of prior ischemic event; ECG changes consistent with myocarditis defined as either diffuse ST elevation or ST-T abnormalities that are documented to be new,; unexplained severe ventricular arrhythmias,; Cardiac MR evidence for myocarditis; Predisposing condition or therapy associated with heightened risk of acute myocarditis (i.e. SARS-CoV-2, Parvovirus, Immune checkpoint inhibitors).
Exclusion: Treatment with potent immunosuppressive therapy beyond corticosteroids; Allergy to ultrasound contrast agents or eggs; Conditions associated with inflammatory myopathy (SLE, giant cell myocarditis, sarcoidosis, etc.); Inability to obtain consent; High pre-test likelihood for ACS based on ECG and history; Pregnancy or planned pregnancy; Lactation.